TABLE 1:
Baseline Clinical Characteristics
| Age (years) | Sex | Transplant to enrollment (years) | Years on SRL monotherapy | Reason for initial SRL conversion¥ | SRL daily dose (trough - ng/ml) | Cause of Liver Disease | Liver Tests (TB/ALT/AlkPhos) | eGFR¥ | Hypertension | Diabetes | Pre-Enrollment Biopsy Features | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TOLERANT GROUP | Inflammation | Ishak Fibrosis | ||||||||||
| 76.3 | F | 7.5 | 4.5 | eGFR 30-60 | 0.5 mg (4.0) | NASH | 0.7/14/72 | 36 | y | n | - | 0/6 |
| 64.4 | M | 4.5 | 3.6 | eGFR 30-60 | 2 mg (4.9) | Alcohol | 0.3/29/97 | 35 | n | y | Minimal portal | 0/6 |
| 56.7 | M | 7.6 | 4.9 | eGFR 30-60 | 1.5 mg (4.7) | NASH | 0.3/16/68 | 46 | n | n | - | 1/6 |
| 64.3 | M | 8.8 | 5.5 | eGFR 30-60 | 1 mg (4.4) | Cryptogenic | 0.4/31/63 | 67 | y | n | NASH Activity Index 3/8 | 1/6 |
| 47.3 | M | 12.1 | 2.4 | eGFR 30-60 | 1 mg (5.0) | Cryptogenic | 0.6/25/92 | 65 | n | n | Rejection Activity Index 2/9 | 1/6 |
| 75.2 | F | 6.9 | 0.6 | eGFR 30-60 | 1 mg (2.2) | Cryptogenic | 0.4/44/108 | 46 | y | n | NASH Activity Index 5/8 | 1/6 |
| 58.8 | M | 10.3 | 4.8 | eGFR 30-60 | 1 mg (3.6) | Alcohol | 0.6/17/89 | 50 | y | y | Minimal portal | 0/6 |
| 64.1 | M | 10.3 | 4.4 | eGFR 30-60 | 1 mg (3.9) | Alcohol | 0.4/25/37 | 46 | y | n | Minimal portal | 0/6 |
| NON-TOLERANT GROUP | ||||||||||||
| 67.1* | M | 5.1 | 3.3 | Hepatoma | 2 mg (4.8) | HCV | 0.5/40/75 | 47 | y | y | - | 1/6 |
| 64.0 | F | 10.9 | 4.9 | eGFR 30-60 | 1 mg (4.3) | Alcohol | 0.4/36/53 | 74 | n | n | NASH Activity Index 5/8 | 0/6 |
| 53.3 | M | 8.8 | 5.4 | eGFR 30-60 | 1 mg (5.6) | Alpha-1 Antitrypsin | 0.6/43/112 | 72 | y | n | Rejection Activity Index 2/9 | 1/6 |
| 67.6 | M | 3.0 | 2.7 | eGFR 30-60 | 1 mg (5.3) | Alcohol | 0.4/23/85 | 45 | n | n | NASH Activity Index 3/8 | 0/6 |
| 62.8 | M | 9.4 | 4.7 | eGFR 30-60 | 1 mg (4.6) | HCV | 0.4/33/73 | 53 | n | n | - | 1/6 |
| 54.4 | F | 6.9 | 4.1 | eGFR 30-60 | 0.5 mg (2.9) | Cryptogenic | 0.7/15/109 | 46 | y | n | Minimal portal | 1/6 |
| 44.0 | M | 3.0 | 2.5 | HEHE | 2 mg (4.5) | HEHE | 1.1/15/56 | 76 | n | n | Minimal portal | 0/6 |
*
Removed due to hepatoma recurrence;
¥
all eGFR values in mL/min/1.73 m2 per MDRD-4.